



2023 Methodological Note – Transparency Declarations under ABPI

I. Introduction

In 2020, Aimmune Therapeutics, Inc. was acquired by Nestlé and became Aimmune Therapeutics, a Nestlé Health Science company, which is a stand-alone business unit that manages Nestlé Health Science's global pharmaceutical business. Aimmune Therapeutics, and its affiliates (i.e. those affiliates that form part of the pharmaceutical business) (collectively "Aimmune"), are committed to ensuring the nature and scope of transfers of value (ToV) provided to healthcare professionals (HCPs), healthcare organisations (HCOs), and other relevant decision makers (ORDMs) are clear and transparent to the public. Therefore, Aimmune has published applicable ToV provided directly or indirectly to HCPs, HCOs, or ORDMs between 1 January 2023 and 31 December 2023, in compliance with the ABPI Code of Practice for the Pharmaceutical Industry 2021 (the "ABPI Code").

In September 2023, Nestlé signed a global agreement with Stallergenes Greer ("Stallergenes") to divest ownership of Aimmune's product, Palforzia®, to Stallergenes. In anticipation of the divestiture of Palforzia, and the subsequent signing of the agreement with Stallergenes, Aimmune's activity with HCPs and HCOs during the 2023 calendar year is significantly less than previous years.

This methodological note is intended to help readers understand how Aimmune collected ToV data and prepared reports for disclosure per the guidelines set forth in the ABPI Code.

II. Data Collection

Aimmune is disclosing applicable ToV that were provided on or after 1 January 2023, based upon the Reporting Date (as defined in section X below).

Aimmune uses a combination of automated systems and manual data collection processes to capture information relating to applicable ToV to HCPs, HCOs, and ORDMs from internal sources and external third parties who make ToV to HCPs/HCOs/ORDMs on behalf of Aimmune. The published information reflects our good faith and best efforts to comply with the disclosure provisions of the ABPI Code.

Despite our best efforts to accurately disclose ToV, if we become aware of a disclosure that appears to be inexact or incomplete, we will review and amend as needed.

Aimmune does not have any "over the counter" medicines or medical devices; therefore, all ToV relate to prescription-only medicines.

This disclosure data is not to be used for any other purposes beyond providing transparency surrounding engagements with HCPs, HCOs, and ORDMs. Aimmune, when disclosing these ToV declarations, does not grant any form of license or authorisation, either special or general, allowing anyone to access these ToV declarations and their content.

III. Definitions

When preparing our disclosures, we applied the definitions found in the ABPI Code for all applicable terms including, but not limited to, “Healthcare Organisation (HCO),” “Healthcare Professional (HCP),” “Transfers of Value (ToV),” “Research and Development,” “Donation,” “Grant,” and “Sponsorship.”

IV. Categories of Disclosure

When preparing our disclosures, we applied the standards found in the ABPI Code for all applicable Categories of Disclosure including, but not limited to, “Collaborative Working,” “Donations and Grants to HCOs,” “Contribution to costs of Events,” and “Contracted Services.”

V. Cross-border Transfers of Value

Cross-border ToV may occur if an Aimmune affiliate provides a ToV to an HCP or HCO whose principal country of practice is different than the location of the Aimmune affiliate (e.g. Aimmune Therapeutics UK Limited may make a payment to a French HCP).

Aimmune will issue one disclosure report for each country showing all ToV made to HCPs, HCOs, and ORDMs in that country, and each report will be published by the relevant Aimmune affiliate for that country and in the manner prescribed by the country (e.g. national platform, company website).

Aimmune discloses ToV based upon the recipient HCP’s principal country of practice. If an HCP practices in more than one country, Aimmune will disclose all ToV to that HCP in the HCP’s principal country of practice.

VI. Indirect Transfers of Value

When preparing our disclosures, we included indirect ToV made to HCPs/HCOs/ORDMs as defined in the ABPI Code. These indirect payments may include work commissioned by Aimmune that is then contracted out to an individual HCP. In such cases, Aimmune coordinates with the contracted service agency to obtain all necessary information for preparing our transparency disclosures.

VII. Data Protection and Aggregate Disclosure

In connection with the collection and processing of HCPs’ personal data, Aimmune complies with all applicable data protection laws.

For data collected prior to August 2022, Aimmune publishes HCPs’ personal data, including details of any ToV provided by Aimmune, subsequent to obtaining consent, unless otherwise specified in an applicable country’s law or regulation regarding transparency.

For data collected from August 2022, Aimmune publishes HCPs’ personal data, including details of any ToV provided by Aimmune, under the lawful basis of Legitimate Interests in order to meet our strong commitment to ethical and transparent collaboration as a member of ABPI.

For ToV in which Aimmune is unable to disclose on an individual basis for legal reasons, including compliance with data protection requirements, Aimmune will disclose on an aggregate basis.

For data collected prior to August 2022, HCPs have the right to withdraw their consent for the individual disclosure of their information at any time. In such cases, any ToV to these individuals will be disclosed on an aggregate basis in a way that does not identify these individuals.

VIII. Currency

Where payments were made in a currency other than the currency of the country in which the disclosure report is made, the payment amount will be converted to the disclosure currency based upon the exchange rate that was in effect on the date the payment was made.

IX. VAT and Other Tax

Aimmune reports ToV as net (i.e. without value added tax or withholding tax) unless the collection of net values is not possible through the particular financial system in which the data was collected.

X. Transfer of Value Reporting Date

Aimmune discloses all ToV based on the date the transfer occurred (the "Reporting Date") (e.g. date meal was provided) or the check date (e.g. if a contract is signed on 01 November 2022 but the check date for consulting services is 05 August 2023, this payment reporting date will be 05 August 2023 and will be published in the 2023 data disclosure report).

XI. Multi-year Projects

Where projects run for several years, such as clinical trials, Aimmune will declare the payment amount relevant to the year in which each part of the payment was made. For example, if a project spans 2 calendar years and includes several individual ToV during each year, Aimmune will make two associated disclosures, one for each calendar year showing the value of the transfers made in each specific calendar year.

XII. Market Research

Market Research payments made to a contracted service agency will not be disclosed if the research is conducted within industry standard principles of market research and the research is either (1) double-blinded or (2) single-blinded where the HCP recipient may know the identity of Aimmune, but Aimmune does not know the identity of the HCP recipient. Any non-blinded Market-Research-related payments (i.e. the identity of the HCP recipient is known to Aimmune) will be disclosed.

XIII. Sponsorships for HCPs to Attend Meetings

Aimmune may support the attendance of HCPs at educational, scientific meetings. Aimmune will disclose the associated Transfers of Value against the individual attendee. Where costs are not individually itemised (e.g. the cost of a bus transferring a group of HCPs from an airport to a conference venue), the total cost will be split equally between all those receiving the benefit.

Costs declared include transport, registration fees, accommodation, and other forms of hospitality.

XIV. HCP Cancellations and No-Shows

If an HCP is invited to an event but does not come to such event, any payments made on the date of the event will not be included as a ToV to the HCP who did not attend. However, if there is ToV that is

not cancellable or reimbursable (e.g. ToV related to accommodation or transport), this ToV will be included in the relevant transparency declarations.

If an event must be cancelled, cancellation fees are not included in transparency declarations.

XV. Grants to HCOs for Support to Attend Medical Meetings

HCOs may make requests inviting Aimmune to provide financial support to assist its employees to attend medical meetings. If Aimmune has agreed to such a request, where the payment is associated with named HCPs, this payment is disclosed as ToV to the named individual HCPs. Where Aimmune is not aware of the identities of the individual HCPs receiving the support, the financial support is declared as a ToV to the named HCO.

XVI. Contributions to Meetings

Aimmune will disclose all payments made to HCOs in relation to meetings. This includes direct funding, such as sponsorship fees or the right to host an exhibition stand, and indirect support such as providing a logistics agency or subsidising the cost of registration fees.

XVII. Payments to HCOs for Services Provided by Individual HCPs

Where services for Aimmune are rendered by an HCP on behalf of an HCO (for example, Aimmune enters into a service contract with an HCO and the services are provided by the HCO's employee who is an HCP), the associated fees and expenses paid by Aimmune to the HCO are disclosed as ToV made to the HCO. This is the case unless Aimmune can confirm that the HCP received a benefit from the ToV, either directly from Aimmune or via the HCO (e.g. fees paid to the HCP in connection with the services he/she rendered and/or reimbursement of any related expenses the HCP incurred), in which case Aimmune will disclose those ToV as being transfers to the HCP.

Where Aimmune can identify the HCP and know that the HCO will make the full ToV to the HCP on Aimmune's behalf, the ToV is disclosed as being a ToV to the HCP. Any "administration fee" charged by the HCO will be disclosed as a ToV fee for the service to that organisation. And if the HCP does not receive any additional payment for the service (e.g. because he/she is speaking at a meeting during normal working hours) then the full amount paid by Aimmune will be disclosed against the HCO as a ToV.

XVIII. Transfers of Value to Patient Organisations

Disclosure data for patient organisations is published on our company website per ABPI Code clause 29.1.

If a ToV is associated with an individual HCP working with a PO, then some or all of the funding may be disclosed in two separate disclosure reports – any ToV provided to the HCP will be disclosed against the individual HCP and in the manner required by the ABPI Code; and the total value of the project will be disclosed as a ToV to the PO on Aimmune's website.

Aimmune will disclose all payments made to POs in relation to meetings. This includes any direct funding that Aimmune may provide to a PO, such as sponsorship fees, and any indirect support, such as providing a logistics agency or subsidising the cost of registration fees.